Investigating Immune Mechanisms in Atopic Eczema

Atopic Dermatitis Clinical Trial

Official title:

Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02102841
• Other study ID #: 13/0410
• Secondary ID: 14/LO/0243
• Status: Withdrawn
• Phase: N/A
• Start date: May 2014
• Est. completion date: May 2017

Study information

• Verified date: April 2021
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to investigate the mechanisms behind the immune dysfunction that occurs in atopic eczema (or atopic dermatitis).

Description:

Atopic eczema is a chronic inflammatory skin disease that affects 15-20% of children and 12% of adults and leads to significant loss of quality of life. It results from a complex interaction of genetic and environmental factors, and is characterised by dysregulation of the cutaneous immune system. Specifically, in the skin of eczema patients there is a persistence of T lymphocytes (a crucial cell involved in regulating the immune system), and an overproduction of certain cytokines (signalling molecules that are essential in producing inflammatory responses).

The study intends to investigate the causes of atopic eczema by examining the number, characteristics and function of T lymphocytes in the skin and the blood of eczema patients, as well as the types of cytokine they produce. To achieve this the investigators aim to take skin biopsies, tissue fluid (from induced skin suction blisters) and blood samples from adult eczema patients and healthy controls for analysis. Additionally, in these groups a cutaneous immune response will be initiated by injecting tuberculin protein purified derivative (the Mantoux test) into the skin, to further investigate how the behaviour of T lymphocytes varies between eczema patients and healthy controls.

This research is important in view of the high prevalence of atopic eczema in the population. An improved understanding of its causes will hopefully lead to more effective treatments for this condition in future.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• History of atopic dermatitis (according to United Kingdom Working Party's diagnostic criteria)

• Previous Bacillus Calmette-Guerin vaccination

Exclusion Criteria:

• Unable to give written informed consent

• Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or tuberculin PPD (for skin test)

• Pregnancy or breast feeding

• History of tuberculosis

• Recent infection or immunisation (within last month)

• Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy

• Systemic steroids within the last month or any other immunosuppressive medications (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months

• Phototherapy within the previous 28 days

• Treatment with potent topical corticosteroids or tacrolimus ointment within the previous 7 days

• Significant co-morbidity (diabetes, renal failure, liver failure, heart failure)

• On warfarin or known bleeding disorder

• History of neoplasm in last 10 years (not including basal cell carcinoma)

• Previous keloid scarring

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic

Intervention

Procedure:
• Skin biopsy

• Skin suction blister

Biological:
• Mantoux test

Locations

Country	Name	City	State
United Kingdom	Royal Free London NHS Foundation Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	Dermatrust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994 Sep;131(3):383-96. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers		Up to 14 days